Literature DB >> 6491911

Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use.

S A Varia, S Schuller, K B Sloan, V J Stella.   

Abstract

Various bioreversible derivatives of phenytoin, a poorly water soluble and erratically absorbed drug after both oral and parenteral dosing, were synthesized. Initial evaluation of these expected prodrugs, i.e., their aqueous solubility, cleavage in the presence of various animal tissues, and anticonvulsant activity in mice, confirmed that a number of the derivatives did indeed behave as prodrugs. The more promising prodrugs were the disodium phosphate ester and various amino groups containing acyl esters of 3-(hydroxymethyl)-5,5-diphenylhydantoin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491911     DOI: 10.1002/jps.2600730812

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Prodrugs. Do they have advantages in clinical practice?

Authors:  V J Stella; W N Charman; V H Naringrekar
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

3.  Acyloxymethyl as a drug protecting group. Part 3. Tertiary O-amidomethyl esters of penicillin G: chemical hydrolysis and anti-bacterial activity.

Authors:  R Moreira; T Calheiros; J Cabrita; E Mendes; M Pimentel; J Iley
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

4.  Phenytoin-lipid conjugates: chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro.

Authors:  G K Scriba
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

5.  The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs.

Authors:  A S Kearney; V J Stella
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

Review 6.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

Review 7.  Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.

Authors:  Soraya S Santos; Rodrigo V Gonzaga; Cauê B Scarim; Jeanine Giarolla; Marina C Primi; Chung M Chin; Elizabeth I Ferreira
Journal:  Front Chem       Date:  2022-02-14       Impact factor: 5.221

8.  Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

Authors:  Yan Zhou; Genyan Zhang; Feng Wang; Jin Wang; Yanwei Ding; Xinyu Li; Chongtie Shi; Jiakui Li; Chengkon Shih; Song You
Journal:  Onco Targets Ther       Date:  2017-10-20       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.